 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Tandem Diabetes Care, Inc. (TNDM) is a medical device company.
The company designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States.
The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump's software.
In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and various pump accessories. Its products in development include t:slim X2 with control IQ technology; t:sport insulin delivery system; and connected (mobile) health offerings.
Shares have formed a bullish cup and handle following its earnings report. On April 30, the company reported a 1st Quarter March 2019 loss of $0.18 per share on revenue of $66.0 million. The consensus estimate was a loss of $0.28 per share on revenue of $50.3 million.
The company said it expects 2019 revenue of $300.0 million to $315.0 million. The company's previous guidance was revenue of $255.0 million to $270.0 million and the current consensus estimate is revenue of $264.3 million for the year ending December 31, 2019. Higher share prices are expected for this stock.
Entry Point: $68.00
Stop Loss: $64.50
Trading Range: $11.38 - $74.81
Target Price: $74.80
TNDM closed at $60.
